ArticleFrontiers in public health2026
Trends and spatial distribution of pulmonary tuberculosis in China: a surveillance study.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tuberculosis (TB) remains a leading infectious cause of death worldwide, and China remains a high-burden country. Pulmonary tuberculosis (PTB) accounts for most TB cases in China, but previous studies have been geographically limited, used short forecasting horizons, or lacked systematic model comparisons. This study aimed to assess trends, spatial dynamics, and future trajectories of PTB incidence and mortality across mainland China and identify geographical anomalies requiring targeted interventions. Methods: Monthly PTB incidence and mortality data for 2004-2025 were obtained from the National Notifiable Disease Reporting System. Joinpoint regression analyzed temporal trends (2004-2023). Global/local Moran's I examined spatial clustering. A rolling-window framework (training: 2004-2021; test: 2022-2025) compared Holt-Winters, SARIMA, Prophet, and XGBoost models, forecasting to 2030. Performance was assessed using MAE, RMSE, MAPE, SMAPE, and the Diebold-Mariano test. Results: During 2004-2023, average annual PTB incidence was 66.23/100,000, and mortality was 0.20/100,000. Incidence peaked in 2005 and then declined significantly from 2006 (APC = -4.37, 95% CI: -7.60 to -3.86%). Mortality also decreased (APC = -2.43, 95% CI: -4.12 to -0.71%). Spatial hotspots shifted from southern China (2004-2008) to western China (Tibet, Xinjiang) after 2008. Liaoning Province exhibited a unique upward mortality trend (AAPC = 7.89%, Conclusion: PTB incidence and mortality in China have declined substantially, but marked geographic disparities persist. Western provinces remain high-burden hotspots, and Liaoning's rising mortality despite low incidence warrants urgent investigation. XGBoost provided the most accurate forecasts, though traditional models also performed reasonably. Geographically tailored interventions, sustained surveillance, and further research into regional anomalies are essential to accelerate progress toward China's 2030 TB elimination targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.